Početna › Multipli mijelom › North Carolina
Kliničke studije za Multipli mijelom u državi North Carolina
52 studija za Multipli mijelom traži sudionike na lokacijama u državi North Carolina.
Gradovi u državi North Carolina
Službeni tekst studije (engleski)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Charlotte
- i još 2
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Levine Cancer Institute, Charlotte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05652335A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Duke University Medical Center, Durham
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Duke University Medical Center, Durham
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06500884A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Atrium Health, Charlotte
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07149857A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina, Chapel Hill
- Durham VAMC, Durham
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
U tijeku regrutacijaFaza 2
Od 60 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06052826A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
- Durham VAMC, Durham
- i još 3
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Levine Cancer Institute, Charlotte
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Atrium Health Levine Cancer Institute, Charlotte
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Medical Center, Chapel Hill
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
- Wake Forest Baptist Health /ID# 271294, Winston-Salem
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06953960Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Novant Health Cancer Institute, Charlotte
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT07555938HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
- Duke University Health System, Durham
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT06822972Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Hillsborough
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT06375044A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chapel Hill
- GSK Investigational Site, Wilson
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Atrium Health, Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlotte
- Research Site, Durham
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- i još 2
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT07764978DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
U tijeku regrutacija
Od 60 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT06296368A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Duke Cancer Center, Durham
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- UNC Hospitals Adult Oncology Clinics, Chapel Hill
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07284758A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 274847, Winston-Salem
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 21. srp 2026. · NCT06892522Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Duke Institute of Cancer/ Duke University, Durham
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 15. srp 2026. · NCT02343042Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 49 godina · Oba spola · Ažurirano 13. srp 2026. · NCT06870760CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- Atrium Health Levine Cancer, Charlotte
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 30 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT06644625A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina /ID# 251203, Chapel Hill
- Atrium Health Wake Forest Baptist Medical Center /ID# 251165, Winston-Salem
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of North Carolina at Chapel Hill, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. srp 2026. · NCT05137054A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- University of North Carolina (Data Collection Only), Chapel Hill
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 6. srp 2026. · NCT06083922Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- i još 4
U tijeku regrutacijaOpažajna studija
Od 65 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT01137825Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Levine Cancer Institute, Charlotte
- Duke University, Durham
- East Carolina University, Greenville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of North Carolina, Chapel Hill
U tijeku regrutacijaFaza 2
Od 19 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT06974786Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill
- Levine Cancer Institute, Charlotte
- Duke Comprehensive Cancer Center, Durham
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lip 2026. · NCT05145400Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Chapel Hill
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 19. svi 2026. · NCT06433947Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.